RUVBL1 and malignant colon neoplasm: Saracatinib is an inhibitor of Lyn,[32] and CB‐6644 is an inhibitor of RUVBL1.[33] The results revealed that the migration and invasion ability of colon cancer cells was significantly reduced after drug intervention in the Lyn/RUVBL1 complex (Figure 2J–K).